Fortress Biotech Inc Stock Price, News & Analysis

Journey Medical (Nasdaq: DERM) has received FDA approval for Emrosi™, a 40 mg minocycline hydrochloride extended-release capsule for treating inflammatory lesions of rosacea in adults. The approval is backed by successful Phase 3 clinical trials where Emrosi demonstrated superior efficacy compared to both Oracea® 40 mg capsules and placebo. The trials met all co-primary and secondary endpoints with no significant safety concerns. Journey Medical plans to launch Emrosi in the U.S. market through its dermatology-focused sales force, with initial supply expected late Q1 or early Q2 2025.

Journey Medical (Nasdaq: DERM) presented data on DFD-29, a minocycline-based treatment for rosacea, at the 44th Fall Clinical Dermatology Conference. The study compared DFD-29 (40mg) with doxycycline (40mg) over 21 days, showing DFD-29 achieved higher dermal concentrations from Day 1. The company's New Drug Application is under FDA review with a PDUFA date of November 4, 2024. The randomized study demonstrated that DFD-29's modified-release formulation maintained consistent plasma levels while providing superior skin penetration compared to doxycycline, with both treatments showing good tolerability.

Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved prescription drugs for dermatological conditions, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference. The event is set to take place on Wednesday, October 9, 2024, in New York City.

Members of Journey Medical's management team will be attending one-on-one meetings during the conference. This participation highlights the company's commitment to engaging with investors and industry professionals in the healthcare sector.

The conference provides an opportunity for Journey Medical to showcase its focus on selling and marketing dermatological treatments, potentially attracting investor interest and fostering business relationships within the pharmaceutical industry.

Fortress Biotech, a biopharmaceutical company focused on acquiring and advancing assets, announced its participation in two upcoming investor conferences in October 2024. Lindsay A. Rosenwald, M.D., the company's Chairman, President, and CEO, will represent Fortress at these events:

1. Lytham Partners Fall 2024 Investor Conference on October 1, 2024, at 4:15 p.m. ET. This virtual event will feature a fireside chat and 1x1 meetings.

2. 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, consisting of 1x1 meetings.

A replay of the Lytham Partners fireside chat will be available on Fortress Biotech's website for approximately 30 days after the event.

Fortress Biotech (Nasdaq: FBIO) has announced a registered direct offering and concurrent private placements totaling approximately $8 million in gross proceeds. The company will issue 3,939,394 shares of common stock (or pre-funded warrants) at $1.65 per share to healthcare-focused institutional investors, along with warrants to purchase an additional 3,939,394 shares at $1.84 per share. In a separate private placement, the company's Chairman, CEO, and President purchased 763,359 shares at $1.84 per share and warrants for the same number of shares.

The offerings are expected to close around September 23, 2024. Fortress Biotech plans to use the net proceeds for operations, including research and development, clinical trials, and working capital. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offerings.

Checkpoint Therapeutics presented longer-term data from its pivotal trial of cosibelimab, an anti-PD-L1 antibody, for advanced cutaneous squamous cell carcinoma (cSCC) at the ESMO Congress 2024. Key highlights include:

- Increased objective response rates (ORRs) of 54.8% and 50.0% in locally advanced and metastatic cSCC, respectively
- Complete response rates improved to 25.8% and 12.8% in locally advanced and metastatic cSCC
- Median duration of response not yet reached in either group
- Manageable safety profile with low rates of severe immune-related adverse events

Checkpoint's Biologics License Application for cosibelimab is under FDA review with a PDUFA goal date of December 28, 2024. The company believes cosibelimab's efficacy and safety profile could position it as a preferred immunotherapy for advanced cSCC if approved.

Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, has announced its participation in the Lake Street Capital Markets 8th Annual Best Ideas Growth (BIG) Conference. The event is set to take place on Thursday, September 12, 2024 in New York City.

Claude Maraoui, President and CEO of Journey Medical, will be attending the conference to engage in one-on-one meetings with investors and industry professionals. This participation underscores the company's commitment to growth and investor relations in the pharmaceutical sector, particularly in the field of dermatology.

Fortress Biotech (Nasdaq: FBIO), an innovative biopharmaceutical company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Lindsay A. Rosenwald, M.D., the company's Chairman, President, and CEO, will present a corporate overview at the event. The presentation will be available for on-demand viewing by conference attendees starting on September 9, 2024, at 7:00 a.m. ET.

Fortress Biotech focuses on acquiring and advancing assets to enhance long-term shareholder value through various revenue streams, including product revenue, equity holdings, and dividend and royalty revenue. The company will also participate in one-on-one meetings during the conference, providing an opportunity for more in-depth discussions with investors and industry professionals.

Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company specializing in FDA-approved dermatological treatments, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Claude Maraoui, President and CEO, will present a corporate overview available for on-demand viewing starting September 9, 2024, at 7:00 a.m. ET.

The company will also engage in one-on-one meetings during the conference. Investors can access a replay of the presentation on Journey Medical's website for approximately 30 days after the event, providing an opportunity to gain insights into the company's strategies and performance in the dermatological pharmaceutical market.